All In Biotech

Drug Trial Radar · NCT05464381

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)

A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB)

Last checked: Nov 20, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

91

Actual

Start

Jun 13, 2023

Primary completion

Aug 29, 2025

Study completion Jan 2027

Sponsor

Lead sponsor
RHEACELL GmbH & Co. KGIndustry
Sponsor type
Industry
First posted
Jul 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo. An additional baseline-controlled open-label arm will be included to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with JEB and to RDEB subjects \< 1 year.

Conditions

  • Epidermolysis Bullosa

Interventions

  • allo-APZ2-OTSDrug

    Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with complete target wound closureTime frame: 6 months

Locations

16 sites in 12 countries. Site status is shown where the registry gives one.

  • Sanatorio Mater Dei

    Buenos Aires, Argentina

  • EB-Haus Austria; Salzburger Landeskliniken (SALK)

    Salzburg, Austria

  • Fundacion Debra Chile

    Santiago, Chile

  • Universitaetsklinik fuer Dermatologie und Allergologie

    Nice, France

  • Hospital Necker-Enfants Malades

    Paris, France

  • Service de Dermatologie Hospital Saint-Louis

    Paris, France

  • Andreas Syggros Hospital of Cutaneous Venereal Diseases

    Athens, Greece

  • Venereal & Skin Diseases Hospital of Thessaloniki

    Thessaloniki, Greece

  • Semmelweis Egyetem

    Budapest, Hungary

  • UOSD Pediatria-Alta Intensita di Curà, Ospedale Maggiore

    Milan, Italy

  • Ospedale Pediatrico Bambin Gesu

    Roma, Italy

  • Medical Concierge Centrum Medyczne

    Warsaw, Poland

  • Centro Hospitalar e Universitario de Comibra HUC

    Coimbra, Portugal

  • Hospital La Paz

    Madrid, Spain

  • Department of Dermatology, National Cheng Kung University

    Tainan, Taiwan

  • Great Ormond Street Hospital (GOSH)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.